Susquehanna International Group
CAPR icon

Susquehanna International Group’s Capricor Therapeutics CAPR Stock Holding History

Susquehanna International Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.9M Sell
259,900
-1,172,100
-82% -$31.2M ﹤0.01% 3480
2025
Q4 		$41.3M Buy
1,432,000
+816,100
+133% +$10.7M ﹤0.01% 1532
2025
Q3 		$4.44M Sell
615,900
-306,800
-33% -$2.26M ﹤0.01% 4267
2025
Q2 		$9.16M Buy
922,700
+744,500
+418% +$7.86M ﹤0.01% 2955
2025
Q1 		$1.69M Buy
178,200
+54,800
+44% +$761K ﹤0.01% 5918
2024
Q4 		$1.7M Buy
123,400
+1,600
+1% +$28K ﹤0.01% 5675
2024
Q3 		$1.85M Buy
121,800
+111,300
+1,060% +$551K ﹤0.01% 5417
2024
Q2 		$50.1K Sell
10,500
-17,400
-62% -$97K ﹤0.01% 11413
2024
Q1 		$189K Sell
27,900
-25,500
-48% -$123K ﹤0.01% 10648
2023
Q4 		$261K Sell
53,400
-6,700
-11% -$21.8K ﹤0.01% 10123
2023
Q3 		$206K Buy
60,100
+48,900
+437% +$275K ﹤0.01% 10170
2023
Q2 		$53.5K Sell
11,200
-5,200
-32% -$22.8K ﹤0.01% 11311
2023
Q1 		$69.2K Sell
16,400
-95,600
-85% -$412K ﹤0.01% 11533
2022
Q4 		$432K Sell
112,000
-40,300
-26% -$192K ﹤0.01% 8245
2022
Q3 		$914K Sell
152,300
-500
-0.3% -$2.56K ﹤0.01% 6865
2022
Q2 		$533K Sell
152,800
-21,700
-12% -$77K ﹤0.01% 8104
2022
Q1 		$599K Sell
174,500
-24,300
-12% -$95.9K ﹤0.01% 8498
2021
Q4 		$582K Sell
198,800
-107,600
-35% -$377K ﹤0.01% 8776
2021
Q3 		$1.23M Buy
306,400
+109,000
+55% +$496K ﹤0.01% 7012
2021
Q2 		$1.01M Sell
197,400
-10,600
-5% -$44.9K ﹤0.01% 7721
2021
Q1 		$973K Buy
208,000
+12,300
+6% +$70.8K ﹤0.01% 7813
2020
Q4 		$671K Sell
195,700
-86,500
-31% -$375K ﹤0.01% 7636
2020
Q3 		$1.48M Buy
282,200
+227,200
+413% +$1.32M ﹤0.01% 5203
2020
Q2 		$253K Buy
+55,000
New +$240K ﹤0.01% 8641

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Susquehanna International Group's CAPR Position: Q1 2026 in Review

Susquehanna International Group reduced its Capricor Therapeutics (CAPR) stake by 31% in Q1 2026, selling an estimated $646K and leaving 53,375 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #6661.

Susquehanna International Group first reported a position in CAPR in Q4 2015 and has held it in 26 quarters since. The position peaked at $3.88M in Q4 2024. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Susquehanna International Group held 53,375 shares of Capricor Therapeutics worth $1.62M as of Q1 2026.
  • Susquehanna International Group sold 24,232 Capricor Therapeutics shares in Q1 2026, an estimated $646K.
  • Capricor Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6661 holding.
  • Susquehanna International Group first reported a position in Capricor Therapeutics in Q4 2015 and has held it in 26 quarters since.
  • Susquehanna International Group's Capricor Therapeutics position peaked at $3.88M in Q4 2024.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.